Leflunomide, a disease-modifying antirheumatic drug (DMARD), has shown effectiveness in many autoimmune disorders and can suppress cytomegalovirus (CMV) disease in humans. Thus, it is possible for leflunomide to play a role in CMV prophylaxis or preemptive therapy in high-risk patients in addition to its application as a DMARD for autoimmune disorders. We describe two adult patients who developed CMV disease after administration of low-dose leflunomide. One patient was successfully treated with an increasing leflunomide dosage, resulting in a long-term suppression of serum CMV viral load.
References
1.
De ClercqE.Antivirals: past, present and future.Biochem Pharmacol2013; 85: 727–744.
2.
Ruiz-CampsI., LenO., de la CamaraR.Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.Antivir Ther2011; 16: 951–957.
3.
KalilA.C., MindruC., FlorescuD F.Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis.Clin Infect Dis2011; 52: 313–321.
4.
AveryR.K.Low-dose valganciclovir for cytomegalovirus prophylaxis in organ transplantation: is less really more?Clin Infect Dis2011; 52: 322–324.
5.
ReischigT., PruchaM., SedlackovaL.Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients.Antivir Ther2011; 16: 1227–1235.
6.
JohnG.T., ManivannanJ., ChandyS., PeterS., JacobC.K.Leflunomide therapy for cytomegalovirus disease in renal allograft recepients.Transplantation2004; 77: 1460–1461.
7.
DunnJ.H., WeinbergA., ChanL.K., MandavaN., LeviM.E., OlsonJ.L.Long-term suppression of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide.JAMA Ophthalmol2013; 131: 958–960.
8.
LeviM.E., MandavaN., ChanL.K., WeinbergA., OlsonJ.L.Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide.Transpl Infect Dis2006; 8: 38–43.
9.
GoldsmithP.M., HusainM.M., CarmichaelA., ZhangH., MiddletonS.J.Case report: multidrug-resistant cytomegalovirus in a modified multivisceral transplant recipient.Transplantation2012; 93: e30–e32.
10.
FarasatiN.A., ShapiroR., VatsA., RandhawaP.Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system.Transplantation2005; 79: 116–118.
11.
DunnM.C., KnightD.A., WaldmanW.J.Inhibition of respiratory syncytial virus in vitro and in vivo by the immunosuppressive agent leflunomide.Antivir Ther2011; 16: 309–317.
12.
JohnG.T., ManivannanJ., ChandyS.A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients.Transplant Proc2005; 37: 4303–4305.
13.
AveryR.K., MossadS.B., PoggioE.Utility of leflunomide in the treatment of complex cytomegalovirus syndromes.Transplantation2010; 90: 419–426.
14.
TeschnerS., BurstV.Leflunomide: a drug with a potential beyond rheumatology.Immunotherapy2010; 2: 637–650.
15.
ChackoB., JohnG.T.Leflunomide for cytomegalovirus: bench to bedside.Transpl Infect Dis2012; 14: 111–120.
